PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[Spideyboy]

Good to see this. Protalix had stated that patients in all the Balance, Bridge and Bright studied will be offered to continue in an extension study.

They already have a trial registered for those patients that have completed either Balance or Bridge, that are both 1mg/kg/2weeks regimen.

For this specific trial, it states the inclusion criteria as having partaken in the Bright study, as that would make sense as they would just be continuing the Bright dosing regimen.

One small curiosity is that for this new study, they mention estimated enrollment at 40, while the Bright study itself was an enrollment of 30. Perhaps they simply expect to continue with all the 30 from Bright and then add another few from the other studies that would see benefit for this 2mg/kg/4week dosing regimen, or enroll new patients entirely.

In either case things seem to be trucking along smoothly.